Why email remains the main vector for advanced cyber-attacks and how ransomware attacks…
Source: www.cshub.com and Read More
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
